KLK14

KLK14

A gene on chromosome 19q13.3-q13.4 that encodes a serine  endopeptidase with a trypsin- and chymotrypsin-like substrate specificity, which may: activate/inactivate proteinase-activated receptors F2R, F2RL1 and F2RL3, as well as other kallikreins (e.g., KLK1, KLK3, KLK5 and KLK11); liquefy seminal clot by cleaving semenogelins SEMG1 and SEMG2 and activating KLK3; cleave desmoglein DSG1, resulting in shedding of superficial keratinocytes from the skin surface; and play a role in tumour progression by affecting growth, invasion and angiogenesis.
Mentioned in ?
References in periodicals archive ?
edu/exomeChip/Proposed Content/codingContent) have indicated the occurrence of stop codons in several KLK genes, including KLK4, KLK9, KLK10, and KLK14.
8] Human genes: KLK3, kallikrein-related peptidase 3; TERT, telomerase reverse transcriptase; FGFR2, fibroblast growth factor receptor 2; TBBX3, T-box protein 3; KLK15, kallikrein-related peptidase 15; KLK2, kallikrein-related peptidase 2; KLK1, kallikrein-related peptidase 1; ACPT, acid phosphatase, testicular; GPR32, G protein-coupled receptor 32; INS, insulin; KLK4, kallikrein-related peptidase 4; KLK9, kallikrein-related peptidase 9; KLK10, kallikrein-related peptidase 10; KLK14, kallikrein-related peptidase 14.
KLK11, KLK13, and KLK14 were measured as previously described (18, 19) (see Supplemental Data section in the online Data Supplement).
The KLK8 mRNAs were considered alone or as a ratio with the KLK5, KLK6, KLK7, KLK10, KLK11, KLK13, or KLK14 mRNA in the same samples.
KLK5, KLK13, and KLK14 may also contribute to tumor cell invasion via degradation of extracellular matrix components (37-39).
Highest concentrations of KLK14 were found in fetal skin and cartilage.
KLK14 was most abundant in CVF, with lower concentrations in seminal plasma, amniotic fluid, and saliva.
Previously, several other kallikreins, including KLK4, KLK5, KLK6, KLK7, KLK8, KLK9, KLK10, KLK11, KLK14, and KLK15, have been associated with various forms of malignancy and especially cancers of the ovary, breast, prostate, and testis [reviewed in Refs.
Telomeric to the last kallikrein gene, KLK14, lies another nonkallikrein gene, Siglec 9, a member of the Siglec multigene family (9,10).
Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.
It is possible that in the future, new members of this gene family may be identified, either centromeric to KLK1 or telomeric to KLK14.
New gene Previous gene New protein symbol (a,b) symbol(s) symbol KLK1 KLK1 hK1 KLK3 KLK3 hK3 KLK2 KLK2 hK2 KLK4 PRSS17, KLK-L1, KLK4 hK4 KLK5 KLK-L2 hK5 KLK6 PRSS9 hK6 KLK7 PRSS6 hK7 KLKS PRSS19 hK8 KLK9 KLK-L3 hK9 KLK10 PRSSL1, hK10 KLK11 PRSS20 hK11 KLK12 KLK-L5 hK12 KLK13 KLK-L4 hK13 KLK14 KLK-L6 hK14 New gene symbol (a,b) Other protein names/symbols KLK1 Pancreatic/renal kallikrein, hPRK KLK3 Prostate-specific antigen, PSA KLK2 Human glandular kallikrein 1, hGK-1 KLK4 Prostase, KLK-L1 protein, EMSP1 KLK5 KLK-L2 protein, HSCTE KLK6 Zyme, protease M, neurosin KLK7 HSCCE KLKS Neuropsin, ovasin, TADG-14 KLK9 KLK-L3 protein KLK10 NES1 protein KLK11 TLSP/hippostasin KLK12 KLK-L5 protein KLK13 KLK-L4 protein KLK14 KLK-L6 protein New gene GenBank symbol (a,b) Accession No.